NCT01006057 - A Trial Investigating the NN1250 Concentration-time Curve in Subjects With Various Degrees of Renal Impairment and in Subjects With Normal Renal Function | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions

DiabetesHealthy

Interventions

DRUG

insulin degludec

Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with end stage renal disease

DRUG

insulin degludec

Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with mild renal impairment

DRUG

insulin degludec

Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with moderate renal impairment

DRUG

insulin degludec

Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in healthy volunteers

DRUG

insulin degludec

Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with severe renal impairment

Trial Locations (1)

Novo Nordisk Investigational Site, Budapest